
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
New York - As the debate continues on the merits of widespread smallpox vaccination, a report in the Journal of Allergy and Clinical Immunology cautioned that vaccines can trigger severe skin reactions among susceptible individuals.






